))
Medtech Deals 'Meaningfully Rebound' in Q1
Manage episode 422896029 series 3241555
Louis Lehot에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Louis Lehot 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
According to a recent PitchBook report, medtech M&A is on the rise, especially with cardiovascular tech and surgical robotics.Key points to note about this recent shift:▪️ Q1 2024 saw $3.3B in funding, up from $2.8B in Q4 2023▪️ Cardiovascular and surgical robotics led the charge with $2.2B and $1B, respectively, in the past year▪️ About 1/2 of the Q1 funding went to later-stage deals.This surge in deal value suggests there could be a strong rest of the year ahead for manda activity. Stabilizing public medtech valuations could further contribute to this trend, allowing for new opportunities for growth and innovation.Give this Axios article a read for more.
Discover more about Louis Lehot and explore additional professional insights on his website: https://louislehot.com
Explore Related Content:
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit louislehotattorney.substack.com
123 에피소드
공유
